Cydan Development Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cydan Development Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12388
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cydan Development Inc (Cydan) is an orphan drug accelerator dedicated to advancing therapies for rare genetic diseases. The company identifies assets with biology and proof-of-concept data in vivo models from academic circles, industry, and other sources. It offers various technology platforms including protein, peptide, nucleic acid, antibody, and AAV gene therapy. Cydan created Imara to develop IMR-687, for the treatment sickle cell disease; and Vtesse which is developing drugs for Niemann-Pick Disease Type C (NPC) and other rare, severe diseases. The company collaborates with patient foundations, academic centres, and biopharmaceutical companies to support drug development. Cydan is headquartered in Cambridge, Massachusetts, the US.

Cydan Development Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cydan Development Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cydan Development Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Cydan Raises USD34 Million in Venture Financing 10
Cydan II (Cydan Development) Raises USD10.66 Million in Venture Financing 12
Cydan Development Raises USD31 Million in Series A Financing 13
Cydan Raises US$26 Million In Venture Financing 14
Equity Offering 16
Vtesse Spin Out from Cydan Development 16
Cydan Development Inc – Key Competitors 17
Cydan Development Inc – Key Employees 18
Cydan Development Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
Apr 09, 2018: Cydan Appoints Chief Business Officer 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Cydan Development Inc, Pharmaceuticals & Healthcare, Key Facts 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cydan Development Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cydan Development Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cydan Raises USD34 Million in Venture Financing 10
Cydan II (Cydan Development) Raises USD10.66 Million in Venture Financing 12
Cydan Development Raises USD31 Million in Series A Financing 13
Cydan Raises US$26 Million In Venture Financing 14
Vtesse Spin Out from Cydan Development 16
Cydan Development Inc, Key Competitors 17
Cydan Development Inc, Key Employees 18
Cydan Development Inc, Subsidiaries 19

List of Figures
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cydan Development Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Cydan Development Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Heidelberg Pharma AG (WL6):企業の財務・戦略的SWOT分析
    Heidelberg Pharma AG (WL6) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • MedinCell SA (MEDCL):製薬・医療:M&Aディール及び事業提携情報
    Summary MedinCell SA (MedinCell) is a developer of therapeutic solutions for the healthcare market. The company develops and commercializes BEPO, a technology based on custom proprietary copolymers and a biocompatible solvent for long acting injectables. Its BEPO provides a controlled release of the …
  • Dialog Group Bhd (DIALOG):企業の財務・戦略的SWOT分析
    Dialog Group Bhd (DIALOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Implants International Ltd:企業の製品パイプライン分析
    Summary Implants International Ltd (Implants International) is a medical device company that manufactures, designs, and develops orthopedic implants, bio-engineering, and other products for the healthcare sector. The company’s products include revision systems, hip stems, hip stem ancillaries, aceta …
  • Sky plc:企業のM&A・事業提携・投資動向
    Sky plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sky plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Pearson plc:企業の戦略・SWOT・財務情報
    Pearson plc - Strategy, SWOT and Corporate Finance Report Summary Pearson plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Mangalore Refinery and Petrochemicals Ltd (MRPL):企業の財務・戦略的SWOT分析
    Mangalore Refinery and Petrochemicals Ltd (MRPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Gas y Petroleo del Neuquen SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Gas y Petroleo del Neuquen SA (Gas Y Petroleo) operates as an oil and gas exploration company. It is engaged in the production and supply of hydrocarbon resources. The company holds 36 contracts with other companies, to develop exploratory and hydrocarbon exploitation activities. It is also …
  • Global Bio-chem Technology Group Company Limited (809):企業の財務・戦略的SWOT分析
    Global Bio-chem Technology Group Company Limited (809) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Ingram Micro Inc.:企業のM&A・事業提携・投資動向
    Ingram Micro Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ingram Micro Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Yext, Inc. (YEXT):企業の財務・戦略的SWOT分析
    Yext, Inc. (YEXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Kitoku Shinryo Co., Ltd.:企業の戦略・SWOT・財務情報
    Kitoku Shinryo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kitoku Shinryo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bio Techne Corp (TECH):製薬・医療:M&Aディール及び事業提携情報
    Summary Bio Techne Corp (Bio Techne), formerly Techne, develops, produces, and markets biotechnology products and scientific tools to understand biological processes and drive research. The company’s portfolio encompasses native and recombinant proteins, monoclonal and polyclonal antibodies, immunoa …
  • Hatch Ltd:企業の戦略的SWOT分析
    Hatch Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Milliken & Co:企業の戦略的SWOT分析
    Milliken & Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Oversea-Chinese Banking Corp Ltd:企業の戦略・SWOT・財務情報
    Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report Summary Oversea-Chinese Banking Corp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Esperion Therapeutics Inc (ESPR)-製薬・医療分野:企業M&A・提携分析
    Summary Esperion Therapeutics Inc (Esperion) is a pharmaceutical company that develops and commercializes oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). The company’s lead product candidate, Bempedoic acid, an ATP-citrate lyase inhibitor which is in Phase …
  • FOX Broadcasting Co:企業の戦略的SWOT分析
    FOX Broadcasting Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • SATT South East SAS-製薬・医療分野:企業M&A・提携分析
    Summary SATT South East SAS (SATT South East), formerly Satt Paca Corse SAS, a subsidiary of SATT Association is a business and consumer services company that offers technology transfer services. The company offers invention disclosure, intellectual property management, economic market, technology c …
  • Xactware Solutions Inc:企業の戦略的SWOT分析
    Xactware Solutions Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆